Advertisement
GYRE vs NKTX
Which Stock Would AI Choose? Gyre Therapeutics (GYRE) vs. Nkarta (NKTX) Stock Comparison
Key Takeaways
- Gyre Therapeutics (GYRE) is a commercial-stage, revenue-generating biopharmaceutical company, while Nkarta (NKTX) is a pre-revenue, clinical-stage developer of cell therapies.
- GYRE's near-term catalyst is regulatory: its New Drug Application (NDA) for F351 (hydronidone) in chronic hepatitis B (CHB)-associated liver fibrosis has been accepted for priority review in China.
- NKTX's near-term catalyst is clinical: initial data from its Ntrust-1 and Ntrust-2 trials of NKX019 in autoimmune disease are expected at a medical conference in 2026.
- GYRE reported revenue and a widening net loss driven by acquisition and launch costs; NKTX reported no revenue and a modest quarterly net loss backed by a cash runway into 2029.
- The two names carry very different risk profiles, with GYRE tied to commercial execution in China and NKTX tied to binary clinical readouts.
Introduction
Investors screening the small-cap biotechnology space often encounter very different business models wearing the same "biotech" label. GYRE and NKTX illustrate that divide well. Gyre Therapeutics generates real product revenue and is navigating a pivotal regulatory milestone, while Nkarta is a clinical-stage developer whose value rests on forthcoming trial data. This stock comparison is relevant for traders assessing relative performance and market positioning, as well as longer-horizon investors weighing commercial-stage stability against clinical-stage upside.
GYRE Overview and Recent Performance
Gyre Therapeutics is a commercial-stage biopharmaceutical company headquartered in San Diego with operations in the United States and China. Its core focus is organ fibrosis and inflammatory diseases, anchored by its lead candidate F351 (hydronidone), a pirfenidone derivative targeting liver fibrosis. Through its majority-owned subsidiary Gyre Pharmaceuticals, the company markets ETUARY (pirfenidone) for idiopathic pulmonary fibrosis (IPF) and other products including nintedanib and avatrombopag.
Recent market activity has centered on regulatory progress rather than revenue growth. In March 2026, China's Center for Drug Evaluation (CDE) granted priority review status to the NDA for F351, and the application was subsequently accepted. In May 2026, Gyre completed its roughly $300 million all-stock acquisition of Cullgen, adding a targeted protein degradation platform. Financially, the company affirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million, though quarterly results swung to a wider net loss as research and development (R&D), marketing, and transaction costs rose. These investments have pressured near-term profitability and weighed on sentiment, even as analysts maintain an average price target well above recent trading levels.
NKTX Overview and Recent Performance
Nkarta is a clinical-stage biotechnology company based in South San Francisco developing engineered natural killer (NK) cell therapies for autoimmune diseases. Its lead candidate, NKX019, is an allogeneic, "off-the-shelf" CAR-NK (chimeric antigen receptor natural killer) therapy targeting CD19, being evaluated in the Ntrust-1 and Ntrust-2 trials across multiple autoimmune indications, including lupus nephritis, systemic sclerosis, and rheumatoid arthritis.
Recent weeks have brought operational rather than financial milestones. Nkarta reached agreement with the U.S. Food and Drug Administration (FDA) to allow outpatient dosing in community settings, broadened its trial network, and continued enrollment at the 4 billion cell per dose level. The company reported no product revenue, a net loss of $40.4 million in its most recent quarter, and cash and investments of $243.2 million as of June 30, 2026, which management expects to fund operations into 2029. Market sentiment remains closely tied to the initial clinical dataset planned for presentation later in 2026, making the stock's trajectory highly dependent on data quality and durability.
Trending AI Robots
For traders who prefer a systematic approach to evaluating setups like the GYRE-versus-NKTX comparison, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, timeframe, performance statistics, and watchlist. Because market conditions change, only a subset of these bots are well suited to the current environment at any given moment, and that is precisely what the Trending AI Robots section highlights. This editorial filtering helps traders surface strategies that are performing well now rather than sifting through an overwhelming catalog. Explore the Trending AI Robots to see which automated approaches are currently in focus.
Head-to-Head Comparison
The most fundamental contrast between these two names is stage. GYRE is commercial-stage, with revenue in the tens of millions per quarter, multiple marketed products, and a controlling stake in a China-based subsidiary. NKTX is pre-revenue, with its entire valuation resting on the clinical and regulatory success of NKX019.
Their growth drivers also differ sharply. GYRE's catalyst is approval-driven: conditional approval of F351 in China would open a new commercial market in liver fibrosis, while its U.S. Investigational New Drug (IND) filing for MASH-associated fibrosis represents a longer-term optionality. NKTX's catalyst is data-driven: positive Ntrust readouts could reposition the company as a leader in CAR-NK cell therapy for autoimmune disease, a field with substantial unmet need but also intense competition.
Risk factors diverge in kind. GYRE faces execution, integration, and China regulatory-policy risk, along with rising operating expenses and recent insider selling activity. NKTX faces binary clinical risk, cash-burn risk, and competitive pressure from rival NK and T-cell platforms. On market positioning, GYRE offers current cash flow and a consensus Buy rating with a notable gap between price and average target, while NKTX offers a longer cash runway relative to burn but no near-term revenue.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely assign a higher relative score to GYRE in the current environment. The company has a defined, near-term catalyst in the form of an accepted, priority-review NDA, existing revenue, and stronger analyst backing, which together suggest greater trend consistency and stability than a pre-revenue clinical-stage peer. That said, NKTX's substantially larger cash position and potential for a transformative data readout give it a distinct asymmetric profile. The AI's preference is probabilistic rather than absolute: GYRE currently offers the more balanced mix of catalysts and commercial footing, while NKTX remains a higher-variance, catalyst-dependent opportunity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and NKTX is a Hold.
GYRE in downward trend: 10-day moving average broke below 50-day moving average on October 15, 2026
The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GYRE as a result. In 75 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for GYRE turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 34 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
GYRE moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 139 of 164 cases where GYRE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.757) is normal, around the industry mean (2.973). P/E Ratio (-29.300) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
NKTX in -3.33% downward trend, sliding for three consecutive days on October 20, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NKTX declined for three days, in 307 of 343 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 25, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTX as a result. In 73 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for NKTX turned negative on September 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
NKTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for NKTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.503) is normal, around the industry mean (2.973). P/E Ratio (-1.094) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
GYRE | NKTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | |
SMR RATING 1..100 | 95 | 97 | |
PRICE GROWTH RATING 1..100 | 76 | 87 | |
P/E GROWTH RATING 1..100 | 97 | 15 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GYRE's Valuation (7) in the null industry is in the same range as NKTX (39). This means that GYRE’s stock grew similarly to NKTX’s over the last 12 months.
GYRE's Profit vs Risk Rating (95) in the null industry is in the same range as NKTX (100). This means that GYRE’s stock grew similarly to NKTX’s over the last 12 months.
GYRE's SMR Rating (95) in the null industry is in the same range as NKTX (97). This means that GYRE’s stock grew similarly to NKTX’s over the last 12 months.
GYRE's Price Growth Rating (76) in the null industry is in the same range as NKTX (87). This means that GYRE’s stock grew similarly to NKTX’s over the last 12 months.
NKTX's P/E Growth Rating (15) in the null industry is significantly better than the same rating for GYRE (97). This means that NKTX’s stock grew significantly faster than GYRE’s over the last 12 months.
| GYRE | NKTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 89% |
| MACD ODDS (%) | 1 day ago 83% | 5 days ago 89% |
| TrendWeek ODDS (%) | 1 day ago 84% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 87% |
| Advances ODDS (%) | 4 days ago 83% | N/A |
| Declines ODDS (%) | 1 day ago 82% | 4 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GYRE’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).
- GYRE’s FA Score: 1 green, 4 red.
- NKTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GYRE’s TA Score shows that 5 TA indicator(s) are bullish while NKTX’s TA Score has 3 bullish TA indicator(s).
- GYRE’s TA Score: 5 bullish, 5 bearish.
- NKTX’s TA Score: 3 bullish, 7 bearish.
Price Growth
GYRE (@Biotechnology) experienced а -8.44% price change this week, while NKTX (@Biotechnology) price change was -9.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was -16.50%, and the average quarterly price growth was -16.80%.
Reported Earning Dates
GYRE is expected to report earnings on Nov 06, 2026.
NKTX is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (+1.05% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GYRE and
Correlation & Price change
A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with TRDA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then TRDA could also see price increases.
| Ticker / NAME | Correlation To GYRE | 1D Price Change % | ||
|---|---|---|---|---|
| GYRE | 100% | -0.68% | ||
| TRDA - GYRE | 41% Loosely correlated | +1.72% | ||
| NKTX - GYRE | 39% Loosely correlated | -0.57% | ||
| RCKT - GYRE | 39% Loosely correlated | +5.00% | ||
| CRSP - GYRE | 39% Loosely correlated | -1.01% | ||
| SPRC - GYRE | 38% Loosely correlated | -10.45% | ||
More | ||||
NKTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with EDIT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | -0.57% | ||
| EDIT - NKTX | 51% Loosely correlated | -0.80% | ||
| CRSP - NKTX | 49% Loosely correlated | -1.01% | ||
| VIR - NKTX | 47% Loosely correlated | -1.32% | ||
| PROK - NKTX | 47% Loosely correlated | -0.69% | ||
| RCKT - NKTX | 46% Loosely correlated | +5.00% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NZF | 11.05 | 0.11 | +1.01% |
| Nuveen Municipal Credit Income Fund | |||
| DECZ | 44.07 | N/A | N/A |
| TrueShares Structured Outcome (December) ETF (DECZ) | |||
| USCI | 110.81 | -0.11 | -0.10% |
| United States Commodity Index Fund (USCI) | |||
| KEMX | 47.73 | -1.45 | -2.95% |
| KraneShares MSCI Emerging Markets EX China Index ETF (KEMX) | |||
| TXXH | 51.41 | -6.23 | -10.81% |
| 21Shares 2x Long HYPE ETF (TXXH) | |||